Physician profile
Eileen Sales
NPI 1518922244
$3,141.32
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $792 · 2020: $392 · 2021: $795 · 2022: $847 · 2023: $315.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $315.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $314.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $969.55 | 2019-2023 | Ubrelvy, Lo Loestrin Fe |
| Pfizer INC. | $393.03 | 2019-2023 | |
| Myovant Sciences INC. | $178.72 | 2021-2022 | |
| Exeltis, USA INC. | $171.24 | 2019-2022 | |
| Avion Pharmaceuticals | $165.33 | 2019-2023 | Balcoltra |
| Therapeuticsmd, INC. | $134.22 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $117.17 | 2021-2023 | |
| Mylan Pharmaceuticals INC. | $93.06 | 2019-2021 | |
| Novo Nordisk INC | $89.47 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $83.78 | 2019-2021 | |
| Aspira Women'S Health INC | $75.21 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $72.16 | 2019-2021 | |
| Shield Therapeutics INC | $56.98 | 2022-2023 | Accrufer |
| Amag Pharmaceuticals, INC. | $54.77 | 2019 | |
| Lupin INC. | $53.54 | 2019-2020 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascend Therapeutics US, LLC | $43.35 | 2021-2023 | |
| Coopersurgical, INC. | $43.34 | 2019-2020 | |
| Astellas Pharma US INC | $36.37 | 2023 | Myrbetriq |
| Minerva Surgical, INC | $35.94 | 2019 | |
| Radius Health, INC. | $26.67 | 2020 | |
| Agile Therapeutics, INC. | $26.36 | 2021-2022 | |
| Duchesnay USA Incorporated | $25.93 | 2019 | |
| Mycovia Pharmaceuticals, INC. | $24.43 | 2023 | Vivjoa |
| Scynexis, INC. | $24.06 | 2022 | |
| Millicent US INC | $20.29 | 2021 | |
| Sanofi Pasteur INC. | $19.37 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $18.54 | 2021 | |
| Hologic Sales and Service, LLC | $16.69 | 2021 | |
| Vertical Pharmaceuticals, LLC | $16.32 | 2019 | |
| Evofem Biosciences, INC. | $14.86 | 2022 | |
| Mission Pharmacal Company | $14.16 | 2019 | |
| Organon LLC | $13.64 | 2022 | |
| Novum Pharma, LLC | $12.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eileen Sales listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.